InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (1 ops.)
Insider track record
CEODisclosed buys
4
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Karbe Frank, Executive. Director active across 4 companies, notably Myovant Sciences Ltd.. Aggregated, 13 filings have been logged. Breakdown: 4 buys · 1 sell. Total volume traded: €154k. History available since 7 July 2021. The latest transaction was disclosed on 7 January 2026 (Disposition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Karbe Frank
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations13 total
7,526 shares@ US$221.5050.9% of flowCommon StockSEC:0001276700-26-000002:0
7,290 shares@ US$219.60100.0% of flowCommon StockSEC:0001610618-25-000102:0
10,500 shares0Common StockSEC:0000950170-25-082458:0
57,500 shares0Common StockSEC:0001610618-25-000012:0
12,500 shares@ US$7.926728.7% of flowCommon StockSEC:0000950170-24-136391:0
Canonical exit: 13 Mar 2025 (T+90)
25,000 shares@ US$10.164571.3% of flowCommon StockSEC:0000950170-24-067365:0
10,500 shares0Common StockSEC:0000950170-24-064820:0
62,500 shares0Common StockSEC:0000950170-23-071939:0
137,005 shares@ €0.664824.0% of flowCommon StockSEC:0000950170-23-035680:0
Canonical exit: 25 Oct 2023 (T+90)
9,000 shares0Common StockSEC:0001209191-23-033007:0
242,424 shares@ €0.75948.4% of flowCommon StockSEC:0000899243-23-011189:0
Canonical exit: 9 Jul 2023 (T+90)
50,000 shares@ €2.096327.6% of flowCommon StockSEC:0000899243-22-031206:0
Canonical exit: 14 Dec 2022 (T+90)
3,232 shares@ US$21.75100.0% of flowCommon SharesSEC:0001209191-21-046171:0
13 of 13 declarations
About Karbe Frank
KARBE FRANK is a corporate insider associated with Phathom Pharmaceuticals, Inc., Better Therapeutics, Inc., Cidara Therapeutics, Inc. and Myovant Sciences Ltd. He has 13 filings in total, and across the sampled recent filings from 2021-07-09 to 2026-01-07, buys amount to EUR 94599 and sells to EUR 1485832, with Attribution shown as the modal transaction nature.
